Janus Henderson Group PLC Invests $11.94 Million in Protara Therapeutics, Inc. (NASDAQ:TARA)

Janus Henderson Group PLC acquired a new position in Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 2,271,832 shares of the company's stock, valued at approximately $11,938,000. Janus Henderson Group PLC owned about 11.01% of Protara Therapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. HBK Investments L P purchased a new position in Protara Therapeutics during the 4th quarter worth approximately $106,000. Dimensional Fund Advisors LP purchased a new position in shares of Protara Therapeutics during the fourth quarter worth $111,000. Bailard Inc. acquired a new position in Protara Therapeutics during the fourth quarter valued at $157,000. Commonwealth Equity Services LLC lifted its position in Protara Therapeutics by 90.4% during the fourth quarter. Commonwealth Equity Services LLC now owns 37,000 shares of the company's stock valued at $195,000 after purchasing an additional 17,572 shares during the period. Finally, 683 Capital Management LLC purchased a new stake in Protara Therapeutics in the fourth quarter valued at $330,000. Institutional investors and hedge funds own 38.13% of the company's stock.

Analyst Upgrades and Downgrades

TARA has been the topic of several analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $23.00 target price on shares of Protara Therapeutics in a report on Monday, April 28th. Cantor Fitzgerald began coverage on Protara Therapeutics in a report on Friday, March 14th. They issued an "overweight" rating on the stock. Scotiabank began coverage on Protara Therapeutics in a research note on Wednesday, April 16th. They set a "sector outperform" rating and a $12.00 target price for the company. Finally, Lifesci Capital initiated coverage on Protara Therapeutics in a research report on Tuesday, March 11th. They set an "outperform" rating and a $22.00 target price on the stock. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $20.40.

Insider Activity

In other news, insider Jacqueline Zummo sold 21,224 shares of Protara Therapeutics stock in a transaction on Wednesday, March 26th. The stock was sold at an average price of $4.53, for a total transaction of $96,144.72. Following the transaction, the insider now owns 98,861 shares in the company, valued at $447,840.33. The trade was a 17.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 8.40% of the company's stock.

Protara Therapeutics Stock Down 6.2%

Shares of Protara Therapeutics stock traded down $0.22 during mid-day trading on Wednesday, reaching $3.27. 201,023 shares of the stock traded hands, compared to its average volume of 769,112. The stock has a market capitalization of $125.97 million, a PE ratio of -1.17 and a beta of 1.73. The business has a 50-day moving average of $3.90 and a 200 day moving average of $4.14. Protara Therapeutics, Inc. has a fifty-two week low of $1.60 and a fifty-two week high of $10.48.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.18. On average, equities research analysts expect that Protara Therapeutics, Inc. will post -3.32 EPS for the current fiscal year.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.